CME/CE

In this expert discussion, Drs. Ravi Savarirayan and Julie Hoover-Fong examine how findings from the PROPEL 3 trial of oral infigratinib fit within the evolving treatment landscape for achondroplasia in children. They review the study's efficacy and safety results in the context of currently available therapies and discuss how these data may inform treatment selection, patient counseling, and shared decision-making. The conversation also explores practical considerations for clinical care and the potential role of emerging therapeutic approaches.

This chapterized expert interview examines six common clinical decision points encountered when incorporating menin inhibitors into the management of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Faculty discuss evidence-informed approaches to treatment initiation, monitoring strategies, drug-drug interaction management, adverse event mitigation, patient counseling, and workflow implementation. Drawing on data from clinical trials and real-world practice considerations, the discussion highlights factors that may influence the selection and use of approved menin inhibitors, including comorbidities, concomitant medications, cardiac risk, and operational complexity. Through a series of clinical debates, learners gain practical insight into optimizing safety, adherence, and treatment delivery while maintaining therapeutic intent.

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.

This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn practical approaches to integrating current and emerging therapies into individualized care plans. The activity also emphasizes proactive adverse event monitoring and management strategies that help patients remain on effective biomarker-directed therapies while maintaining quality of life.

This online activity is designed to provide the healthcare team with the latest developments and critical insights into Hodgkin lymphoma treatment. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

This online education activity will clearly and accurately present recent clinical trial data evidencing superior outcomes for adults and children with cHL who are treated with ICIs, compared with established chemotherapy regimens and/or brentuximab vedotin, in both the R/R and frontline settings.

In this expert discussion, Drs. Michael Levine and Aliya Khan review emerging evidence in autosomal dominant hypocalcemia type 1 (ADH1), including findings from the CALIBRATE trial presented at ENDO 2026. They discuss how CaSR-targeted therapy with encaleret may address the underlying disease mechanism and highlight key efficacy and safety findings, including reductions in hypercalciuria and the potential implications for long-term renal health. The faculty also examine the role of genetic testing in establishing an accurate diagnosis, guiding family screening, and preparing clinicians for emerging precision medicine approaches in ADH1.

While anti-VEGF biologics have transformed outcomes in neovascular age-related macular degeneration (nAMD), real-world data continue to show that visual gains achieved in clinical trials are not consistently replicated in practice due to various reasons. As sustained-delivery tyrosine kinase inhibitors (TKIs) advance through late-stage development, retina specialists are confronted with complex mechanistic distinctions, extracellular ligand sequestration versus intracellular receptor inhibition, pan-VEGFR activity, IL-6 pathway modulation, and potential effects on vascular stability, that carry meaningful implications for durability, disease control, and patient selection. The pivotal trials evaluating these TKIs also differ in terms of study design, statistical frameworks, and study endpoints, and without structured guidance, clinicians risk making inappropriate cross-trial comparisons, misinterpreting statistical intent, or overgeneralizing durability signals. This educational activity has been designed to analyze the mechanistic differences between TKIs and their relation to clinically relevant decision points and the key differences in TKI trial designs in nAMD.